Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment ...

Princess Anne has been dealt a blow as the royal's plane "struggled to land" amid extreme weather conditions. The Princess ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Key data to be presented at HIV Glasgow 2024 by ViiV Healthcare and its study partners will include: Analysis of cabotegravir + rilpivirine long-acting (CAB+RPV LA) in the real-world and across ...

These data were presented at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 – 13 November. DOLCE is a randomised, open-label, multicentre study assessing the efficacy and safety of DTG/3TC ...

DE BILT, Netherlands & GLASGOW, Scotland–(BUSINESS WIRE)–Code Pharma today announced positive eight-week results for human ...

We look forward to sharing additional insights at the HIV Glasgow meeting next week, including persistence data from PURPOSE ...

Peripartum HIV transmission can be reduced to under 5 ... Division of Developmental Medicine, University of Glasgow Medical Faculty, Glasgow, UK. Disclosure: The authors have no relevant ...

Kidney transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV is an emerging practice. It has been performed since 2016 under the U.S. congressional HIV Organ ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...